Potential COVID-19 treatment and vaccine combination shows success in cells
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
List view / Grid view
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
Researchers have sequenced SARS-CoV-2, revealing at least six strains with little variability, useful information for vaccine developers.
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
Researchers have created compounds called 3C-like protease inhibitors which demonstrated antiviral activity against several coronaviruses in cells, including COVID-19.
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
Researchers say computational analyses suggest the bradykinin system may explain some of the symptoms of COVID-19, providing a drug target.
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.